表紙
市場調查報告書

BRAF激化酵素抑制劑的全球市場:2019年∼2023年

Global BRAF Kinase Inhibitors Market 2019-2023

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 865018
出版日期 內容資訊 英文 125 Pages
訂單完成後即時交付
價格
Back to Top
BRAF激化酵素抑制劑的全球市場:2019年∼2023年 Global BRAF Kinase Inhibitors Market 2019-2023
出版日期: 2019年05月17日內容資訊: 英文 125 Pages
簡介

Dabrafenib及Sorafenib等的BRAF激化酵素抑制劑為基礎優秀藥物,帶給HCC、RCC、NSCLC,及黑色素瘤的治療策略革命。然而,這些藥物的高成本,對患者和醫療系統來說都是課題。為了克服這個課題,包含製藥公司的許多政府機關及非政府機關,為各種癌症適應症的治療致力提供財政支援及臨床性支援。有效的患者支援計劃和償付計劃,預期成為BRAF激化酵素抑制劑的高成本治療方法的一大幫助,利用治療方法的患者增加般促進,據此促進市場成長。 Technavio的分析師預測,全球BRAF激化酵素抑制劑市場至2023年預計將以8%以上的年複合成長率成長。

本報告提供全球BRAF激化酵素抑制劑市場相關調查分析,市場規模與成長率,市場趨勢,市場的推動要素與課題,市場機會驗證,再加上主要供應商等相關的系統性資訊。

目錄

第1章 摘要整理

第2章 報告的範圍

  • 簡介1
  • 簡介2
  • 美金的貨幣換算比率

第3章 市場情形

  • 市場生態系統
  • 市場特徵
  • 市場區隔分析

第4章 市場規模

  • 市場定義
  • 市場規模(2018年)
  • 市場規模及預測(2018年∼2023年)

第5章 波特的五力分析

  • 買主談判力
  • 供應商談判力
  • 新加入廠商的威脅
  • 替代品的威脅
  • 競爭對手的威脅
  • 市場情況

第6章 市場區隔:各產品

  • 市場區隔:各產品
  • 各產品比較:市場規模及預測(2018年∼2023年)
  • Dabrafenib
  • Sorafenib
  • Vemurafenib
  • Encorafenib
  • 市場機會:各產品

第7章 客戶形勢

第8章 地區形勢

  • 各地區市場區隔
  • 各地區比較:市場規模及預測(2018年∼2023年)
  • 北美
  • 歐洲
  • 亞洲
  • 其他地區
  • 主要國家
  • 市場機會

第9章 成長要素與課題

  • 市場成長要素
  • 市場課題

第10章 市場趨勢

第11章 業者情勢

  • 概要
  • 創造性破壞狀況
  • 競爭模式

第12章 供應商分析

  • 交易廠商
  • 供應商分類
  • 供應商的市場定位
  • Array BioPharma Inc.
  • Bayer AG
  • F. Hoffmann-La Roche Ltd.
  • Novartis AG

第13章 附錄

  • 調查方法
  • 簡稱的清單
  • 供應商的市場定位定義

第14章 關於TECHNAVIO

目錄
Product Code: IRTNTR31351

About this market

Prominent drugs based on BRAF kinase inhibitors, such as dabrafenib and sorafenib, are revolutionizing the therapeutic strategies of HCC, RCC, NSCLC, and melanomas. However, the high costs of these drugs remain a challenge to patients as well as the healthcare system. To overcome this challenge, many government and non-government organizations, including pharmaceutical companies, are focusing on providing financial assistance and clinical assistance for the treatment of various cancer indications. Effective patient assistance programs and reimbursement programs are expected to help with the high-cost regimen of BRAF kinase inhibitors to a large extent, which would encourage more patients to avail the treatment, thereby driving the market growth. Technavio's analysts have predicted that the BRAF kinase inhibitors market will register a CAGR of over 8% by 2023.

Market Overview

Increasing prevalence of cancer

The prevalence of cancer has seen a significant rise in recent years globally, and the global pharmaceuticals market has witnessed the approval of various novel therapies, especially in the field of oncology. Hence, various companies are conducting heavy research on developing novel therapeutics, such as BRAF kinase inhibitors, to capture the huge unmet need, and the market has witnessed the approval of these drugs in the last two decades. Currently, BRAF kinase inhibitors are approved for some of the major cancers such as NSCLC, metastatic melanomas, and RCC. Therefore, the strong prevalence of various cancer indications is driving the growth of the global BRAF kinase inhibitors market.

Adverse effects of available drugs

BRAF kinase inhibitor therapeutics demonstrate a range of adverse effects such as fatigue, muscle cramps, nausea, vomiting, and diarrhea. The combination of BRAF kinase inhibitors and radiation therapy often leads to cytotoxic effects and myelosuppression. Despite being highly efficacious, the BRAF kinase inhibitors used for treating some of the oncology indications are associated with a spectrum of side effects. These side effects limit patient adherence to treatments, which poses a challenge to the market.

For the detailed list of factors that will drive and challenge the growth of the BRAF kinase inhibitors market during 2019-2023.

Competitive Landscape

The market appears to be moderately concentrated. The presence of few companies, including Array BioPharma Inc. and Bayer AG makes the competitive environment quite intense. Factors such as the improvements in production technology of BRAF kinase inhibitors and the growing demand for renewable energy and sustainable products will provide significant growth opportunities to the BRAF kinase inhibitor drug manufacturers. F. Hoffmann-La Roche Ltd., and Novartis AG. are some of the major companies covered in this report.

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1 Preface
  • 2.2 Preface
  • 2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: MARKET SEGMENTATION BY PRODUCT

  • Market segmentation by product
  • Comparison by product
  • Dabrafenib - Market size and forecast 2018-2023
  • Sorafenib - Market size and forecast 2018-2023
  • Vemurafenib - Market size and forecast 2018-2023
  • Encorafenib - Market size and forecast 2018-2023
  • Market opportunity by product

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 09: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 10: MARKET TRENDS

PART 11: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption
  • Competitive scenario

PART 12: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Array BioPharma Inc.
  • Bayer AG
  • F. Hoffmann-La Roche Ltd.
  • Novartis AG

PART 13: APPENDIX

  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors

PART 14: EXPLORE TECHNAVIO

List of Exhibits

  • Exhibit 01: Global pharmaceuticals market
  • Exhibit 02: Segments of global pharmaceuticals market
  • Exhibit 03: Market characteristics
  • Exhibit 04: Market segments
  • Exhibit 05: Market definition - Inclusions and exclusions checklist
  • Exhibit 06: Market size 2018
  • Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
  • Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
  • Exhibit 09: Five forces analysis 2018
  • Exhibit 10: Five forces analysis 2023
  • Exhibit 11: Bargaining power of buyers
  • Exhibit 12: Bargaining power of suppliers
  • Exhibit 13: Threat of new entrants
  • Exhibit 14: Threat of substitutes
  • Exhibit 15: Threat of rivalry
  • Exhibit 16: Market condition - Five forces 2018
  • Exhibit 17: Product - Market share 2018-2023 (%)
  • Exhibit 18: Comparison by product
  • Exhibit 19: Dabrafenib - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 20: Dabrafenib - Year-over-year growth 2019-2023 (%)
  • Exhibit 21: Sorafenib - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 22: Sales data of sorafenib
  • Exhibit 23: Sorafenib - Year-over-year growth 2019-2023 (%)
  • Exhibit 24: Vemurafenib - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 25: Vemurafenib - Year-over-year growth 2019-2023 (%)
  • Exhibit 26: Encorafenib - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 27: Encorafenib - Year-over-year growth 2019-2023 (%)
  • Exhibit 28: Market opportunity by product
  • Exhibit 29: Customer landscape
  • Exhibit 30: Market share by geography 2018-2023 (%)
  • Exhibit 31: Geographic comparison
  • Exhibit 32: North America - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 33: North America - Year-over-year growth 2019-2023 (%)
  • Exhibit 34: Top 3 countries in North America
  • Exhibit 35: Europe - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 36: Europe - Year-over-year growth 2019-2023 (%)
  • Exhibit 37: Top 3 countries in Europe
  • Exhibit 38: Asia - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 39: Asia - Year-over-year growth 2019-2023 (%)
  • Exhibit 40: Top 3 countries in Asia
  • Exhibit 41: ROW - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 42: ROW - Year-over-year growth 2019-2023 (%)
  • Exhibit 43: Top 3 countries in ROW
  • Exhibit 44: Key leading countries
  • Exhibit 45: Market opportunity
  • Exhibit 46: Patient assistance programs
  • Exhibit 47: New cases of cancer in the US 2015
  • Exhibit 48: Alternative therapies based on BRAF kinase inhibitors for various oncology indications
  • Exhibit 49: Side effects of BRAF kinase inhibitors
  • Exhibit 50: Impact of drivers and challenges
  • Exhibit 51: Approved drugs with respect to their cancer indications
  • Exhibit 52: Expansion of research areas of BRAF kinase inhibitors
  • Exhibit 53: Strategic alliances in global BRAF kinase inhibitors market
  • Exhibit 54: Vendor landscape
  • Exhibit 55: Landscape disruption
  • Exhibit 56: Vendors covered
  • Exhibit 57: Vendor classification
  • Exhibit 58: Market positioning of vendors
  • Exhibit 59: Array BioPharma Inc. - Vendor overview
  • Exhibit 60: Array BioPharma Inc. - Business segments
  • Exhibit 61: Array BioPharma Inc. - Organizational developments
  • Exhibit 62: Array BioPharma Inc. - Geographic focus
  • Exhibit 63: Array BioPharma Inc. - Key offerings
  • Exhibit 64: Array BioPharma Inc. - Key customers
  • Exhibit 65: Bayer AG - Vendor overview
  • Exhibit 66: Bayer AG - Business segments
  • Exhibit 67: Bayer AG - Organizational developments
  • Exhibit 68: Bayer AG - Geographic focus
  • Exhibit 69: Bayer AG - Segment focus
  • Exhibit 70: Bayer AG - Key offerings
  • Exhibit 71: Bayer AG - Key customers
  • Exhibit 72: F. Hoffmann-La Roche Ltd. - Vendor overview
  • Exhibit 73: F. Hoffmann-La Roche Ltd. - Business segments
  • Exhibit 74: F. Hoffmann-La Roche Ltd. - Organizational developments
  • Exhibit 75: F. Hoffmann-La Roche Ltd. - Geographic focus
  • Exhibit 76: F. Hoffmann-La Roche Ltd. - Segment focus
  • Exhibit 77: F. Hoffmann-La Roche Ltd. - Key offerings
  • Exhibit 78: F. Hoffmann-La Roche Ltd. - Key customers
  • Exhibit 79: Novartis AG - Vendor overview
  • Exhibit 80: Novartis AG - Business segments
  • Exhibit 81: Novartis AG - Organizational developments
  • Exhibit 82: Novartis AG - Geographic focus
  • Exhibit 83: Novartis AG - Segment focus
  • Exhibit 84: Novartis AG - Key offerings
  • Exhibit 85: Novartis AG - Key customers
  • Exhibit 86: Validation techniques employed for market sizing
  • Exhibit 87: Definition of market positioning of vendors
Back to Top